查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1953394

兒童癌症生物標記市場－全球產業規模、佔有率、趨勢、機會及預測（按適應症、類型、最終用途、地區和競爭格局分類，2021-2031年）

Pediatric Cancer Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Type, By End-Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球兒童癌症生物標記市場預計將從 2025 年的 8.1553 億美元大幅成長至 2031 年的 13.9378 億美元，複合年成長率達到 9.34%。

兒童癌症生物標記，包括特定的生物分子和基因突變，是診斷、預測預後和監測兒童惡性腫瘤治療效果的重要工具。推動這一市場成長的主要因素是精準腫瘤學的日益普及，其旨在基於精確的分子譜分析實現個體化治療，從而最大限度地減少對發育中生理功能的長期副作用。此外，微創診斷技術（例如液態生物檢體）的興起也促進了市場發展，與傳統的組織切片檢查相比，液體活體組織切片能夠提供更快捷的檢測方法。

市場概覽
預測期 2027-2031
市場規模：2025年 8.1553億美元
市場規模：2031年 13.9378億美元
複合年成長率：2026-2031年 9.34%
成長最快的細分市場 白血病
最大的市場 北美洲

儘管取得了這些進展，但該領域仍面臨著許多挑戰，例如兒童腫瘤樣本的有限性和兒童癌症的生物學複雜性等因素阻礙了全面的臨床檢驗。統計數據凸顯了此類診斷解決方案的迫切需求：根據美國癌症研究協會（AACR）預測，到2025年，全球每年將有約40萬名兒童罹患癌症。如此沉重的負擔凸顯了開發可靠的生物標記的緊迫性，然而，招募足夠的兒童患者群體以獲得監管部門核准所面臨的後勤挑戰仍然是快速商業化的主要瓶頸。

市場促進因素

精準醫療的加速發展正在從根本上改變市場格局，它優先考慮特定的分子譜分析，而非廣泛的干涉措施。隨著臨床醫生擴大利用基因組數據來檢測可治療的突變，能夠指導免疫療法和激酶抑制劑選擇的檢測需求也隨之飆升。這項轉變旨在改善復發或難治性癌症兒童的治療效果，同時降低傳統化療帶來的毒性。美國癌症研究協會 (AACR) 於 2025 年 12 月發布的《2025 年 AACR兒童癌症進展報告》也印證了這一趨勢。報告指出，2015 年至 2025 年間，美國食品藥物管理局 (FDA)核准了20 多種分子標靶療法和 10 多種免疫療法用於治療兒童癌症，並強調了生物標記在為患者匹配這些先進療法方面的重要性日益凸顯。

同時，政府撥款和學術津貼的增加為降低兒童專用診斷工具研發風險提供了必要的資金。由於兒童腫瘤領域規模小於成人市場，公共部門的支持對於支付生物標記發現和檢驗的高昂成本至關重要。例如，美國國立衛生研究院 (NIH) 於 2025 年 9 月宣布，將把其兒童癌症數據舉措的年度預算增加一倍，達到 1 億美元，以加快數據生成和分析。此外，消除全球差異仍然是重點關注的問題。世界衛生組織 (WHO) 2025 年的報告預測，高所得國家的存活率將超過 80%，而中低收入國家的存活率仍低於 30%，這凸顯了開發經濟有效的生物標記解決方案以改善全球早期診斷的緊迫性。

市場挑戰

全球兒童癌症生物標記市場成長的主要障礙在於兒童腫瘤樣本的稀缺性以及這些癌症固有的生物學異質性。與成人惡性腫瘤相比，兒童癌症較為罕見，具有獨特的生物學特徵，並且通常具有獨特的基因突變，這些突變在不同患者之間差異顯著。這種多樣性要求進行廣泛的研究來驗證新型生物標記的臨床療效，但高品質組織樣本的有限供應使得獲取監管申報所需的具有統計意義的數據變得極其困難。因此，診斷公司面臨著漫長的研發週期和不斷上漲的成本，抑制了投資並延緩了精準檢測平台的應用。

這項根本限制嚴重限制了市場參與企業快速拓展產品系列的能力。對於這些發生率低於成人癌症的疾病而言，招募足夠的受試者尤其困難。根據美國癌症協會估計，2024年美國將有9,620名0至14歲的兒童被診斷出罹患癌症。如此小規模的患者群體在臨床試驗招募方面造成了嚴重的瓶頸，直接阻礙了新型生物標記的檢驗，並最終減緩了整體市場擴張。

市場趨勢

微小殘留疾病（MRD）檢測的廣泛應用已成為一項重要的市場趨勢，其驅動力在於對更高靈敏度的治療反應評估和復發預測的需求。除了傳統的形態學評估外，先進的MRD檢測已成為臨床試驗和監管核准的重要組成部分，並經常被用作檢驗新型療法療效的主要終點。 MRD狀態在骨髓惡性腫瘤治療策略指南中的應用日益廣泛，也印證了這一發展趨勢。例如，亞盛醫藥在2025年12月發布的新聞稿中宣布，FDA和EMA核准了其針對新診斷的Ph+ ALL患者的3期POLARIS-1試驗。新聞稿指出，該公司聯合治療在三個療程後實現了約65%的分子MRD陰性率，凸顯了檢測在證明新型藥物臨床價值方面發揮的關鍵作用。

同時，功能性精準醫學檢測的興起標誌著治療評估方式正從靜態基因組分析轉向動態評估，包括藥物敏感性和暴露程度。這些功能性生物標記能夠幫助臨床醫生最佳化給藥方案，並降低因藥物濃度不足而導致的復發風險。對轉化研究的大量投入正推動著這些標誌物的檢驗。值得注意的是，2024年12月，紀念斯隆-凱特琳癌症中心在《MSK Kids 2024：兒童癌症臨床和研究進展亮點》報告中指出，該中心已獲得美國國防部440萬美元的津貼，用於開展INFLUENCE試驗。該試驗利用功能性檢測來接受兒童白血病患者的復發風險。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球兒童癌症生物標記市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 根據適應症（白血病、神經母細胞瘤、中樞神經系統腫瘤、淋巴瘤、其他）
    • 依類型（胎兒球蛋白(AFP)、神經元特異性烯醇化酶 (NSE)、CD19、CD20、CD22、ALK（間變性淋巴瘤受體蛋白酪氨酸激酶基因）、其他）
    • 透過申請（醫院、診斷檢查室、腫瘤中心、研究機構）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美兒童癌症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲兒童癌症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區兒童癌症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲兒童癌症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美兒童癌症生物標記市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球兒童癌症生物標記市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Qiagen
  • Abbott
  • Illumina
  • Bio-Rad
  • Myriad Genetics
  • Agilent
  • Roche
  • Takara Bio

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25328

The Global Pediatric Cancer Biomarkers Market is projected to expand significantly, growing from USD 815.53 Million in 2025 to USD 1393.78 Million by 2031, achieving a compound annual growth rate of 9.34%. Pediatric cancer biomarkers, which encompass specific biological molecules or genetic alterations, are essential tools for diagnosing, prognosing, and monitoring therapeutic responses in childhood malignancies. A primary engine of this growth is the increasing integration of precision oncology, which relies on accurate molecular profiling to customize treatments and minimize long-term adverse effects in developing physiologies. Furthermore, the market is being bolstered by a shift toward minimally invasive diagnostic techniques, such as liquid biopsies, which offer faster testing alternatives compared to conventional tissue biopsies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 815.53 Million
Market Size 2031USD 1393.78 Million
CAGR 2026-20319.34%
Fastest Growing SegmentLeukemia
Largest MarketNorth America

Despite these advancements, the sector faces substantial obstacles due to the rarity of pediatric tumor samples and the biological complexity of childhood cancers, both of which impede comprehensive clinical validation. Statistical data underscores the critical necessity for these diagnostic solutions; according to the American Association for Cancer Research, approximately 400,000 children globally are expected to develop cancer annually in 2025. While this heavy burden highlights the urgent requirement for robust biomarker development, the logistical challenges associated with recruiting sufficient pediatric patient cohorts for regulatory approval continue to act as a major bottleneck to rapid commercialization.

Market Driver

The market is being fundamentally transformed by an accelerated transition toward precision medicine, which prioritizes specific molecular profiling over broad-spectrum interventions. As clinicians increasingly utilize genomic data to detect actionable alterations, there is a surging demand for assays capable of guiding the selection of immunotherapies and kinase inhibitors. This shift aims to lower the toxicity linked to traditional chemotherapy while enhancing outcomes for young patients with relapsed or refractory conditions. The "AACR Pediatric Cancer Progress Report 2025," released by the American Association for Cancer Research in December 2025, validates this trend by noting that the FDA approved over 20 molecularly targeted therapies and more than 10 immunotherapies for pediatric cancers between 2015 and 2025, highlighting the growing reliance on biomarkers to match patients with these advanced treatments.

Concurrently, increased government funding and academic grants are supplying the necessary capital to mitigate risks associated with developing pediatric-specific diagnostic tools. Given that the pediatric oncology sector is smaller than the adult market, public sector backing is vital for covering the substantial costs of biomarker discovery and validation. For instance, the National Institutes of Health announced in September 2025 that it would double the annual budget for the Childhood Cancer Data Initiative to $100 million to expedite data generation and analysis. Additionally, addressing global disparities remains a key focus; according to the World Health Organization in 2025, survival rates exceed 80% in high-income countries but remain below 30% in low- and middle-income nations, emphasizing the urgent need for cost-effective biomarker solutions to enhance early diagnosis globally.

Market Challenge

A primary obstacle impeding the growth of the Global Pediatric Cancer Biomarkers Market is the scarcity of pediatric tumor samples combined with the inherent biological heterogeneity of these cancers. In contrast to adult malignancies, childhood cancers are rare and biologically distinct, often characterized by unique genetic alterations that vary significantly among patients. This diversity requires extensive studies to prove the clinical validity of new biomarkers, yet the limited supply of high-quality tissue samples makes it extremely challenging to produce the statistically significant data needed for regulatory submissions. As a result, diagnostic companies encounter extended development timelines and increased costs, factors that deter investment and delay the introduction of precision testing platforms.

This fundamental constraint severely limits the capacity of market participants to rapidly broaden their product portfolios. The challenge of recruiting sufficient study cohorts is highlighted by the low incidence rates of these conditions relative to adult cancers. According to the American Cancer Society, an estimated 9,620 children aged birth to 14 years were diagnosed with cancer in the United States in 2024. This comparatively small patient population creates a significant bottleneck for clinical trial recruitment, which directly hampers the validation of novel biomarkers and consequently stalls the overall expansion of the market.

Market Trends

The widespread adoption of Minimal Residual Disease (MRD) testing is emerging as a critical market trend, driven by the necessity to evaluate treatment efficacy and predict relapse with superior sensitivity. Moving beyond traditional morphological assessments, advanced MRD assays have become essential components of clinical trials and regulatory approvals, frequently serving as primary endpoints for validating new therapeutics. This evolution is illustrated by the growing use of MRD status to direct treatment strategies in hematologic malignancies. For example, in December 2025, Ascentage Pharma reported in its press release regarding the "FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL" that its combination therapy achieved a molecular MRD-negativity rate of roughly 65% after three cycles, underscoring the test's pivotal role in proving the clinical value of new drugs.

Simultaneously, the rise of Functional Precision Medicine Assays represents a move beyond static genomic profiling toward the evaluation of dynamic therapeutic responses, including drug sensitivity and exposure levels. These functional biomarkers enable clinicians to refine dosing regimens and reduce relapse risks associated with inadequate drug concentrations. The momentum to validate these markers is bolstered by significant investment in translational research. A notable example occurred in December 2024, when Memorial Sloan Kettering Cancer Center reported in its "MSK Kids 2024: Highlights of Clinical and Research Advances for Pediatric Cancers" that it had received a $4.4 million grant from the U.S. Department of Defense for the INFLUENCE Trial, which employs functional assays to address relapse risks in pediatric leukemia patients.

Key Market Players

  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Qiagen
  • Abbott
  • Illumina
  • Bio-Rad
  • Myriad Genetics
  • Agilent
  • Roche
  • Takara Bio

Report Scope

In this report, the Global Pediatric Cancer Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Cancer Biomarkers Market, By Indication

  • Leukemia
  • Neuroblastoma
  • CNS Tumors
  • Lymphoma
  • Others

Pediatric Cancer Biomarkers Market, By Type

  • Alpha-fetoprotein (AFP)
  • Neuron-specific enolase (NSE)
  • CD19
  • CD20
  • CD22
  • ALK (anaplastic lymphoma receptor tyrosine kinase gene)
  • Others

Pediatric Cancer Biomarkers Market, By End-Use

  • Hospital
  • Diagnostic Laboratories
  • Oncology Centers
  • Research Institutions

Pediatric Cancer Biomarkers Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Cancer Biomarkers Market.

Available Customizations:

Global Pediatric Cancer Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Cancer Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma, Others)
    • 5.2.2. By Type (Alpha-fetoprotein (AFP), Neuron-specific enolase (NSE), CD19, CD20, CD22, ALK (anaplastic lymphoma receptor tyrosine kinase gene), Others)
    • 5.2.3. By End-Use (Hospital, Diagnostic Laboratories, Oncology Centers, Research Institutions)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pediatric Cancer Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Type
    • 6.2.3. By End-Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pediatric Cancer Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End-Use
    • 6.3.2. Canada Pediatric Cancer Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End-Use
    • 6.3.3. Mexico Pediatric Cancer Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End-Use

7. Europe Pediatric Cancer Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Type
    • 7.2.3. By End-Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pediatric Cancer Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End-Use
    • 7.3.2. France Pediatric Cancer Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End-Use
    • 7.3.3. United Kingdom Pediatric Cancer Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End-Use
    • 7.3.4. Italy Pediatric Cancer Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End-Use
    • 7.3.5. Spain Pediatric Cancer Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End-Use

8. Asia Pacific Pediatric Cancer Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Type
    • 8.2.3. By End-Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pediatric Cancer Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End-Use
    • 8.3.2. India Pediatric Cancer Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End-Use
    • 8.3.3. Japan Pediatric Cancer Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End-Use
    • 8.3.4. South Korea Pediatric Cancer Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End-Use
    • 8.3.5. Australia Pediatric Cancer Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End-Use

9. Middle East & Africa Pediatric Cancer Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Type
    • 9.2.3. By End-Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pediatric Cancer Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End-Use
    • 9.3.2. UAE Pediatric Cancer Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End-Use
    • 9.3.3. South Africa Pediatric Cancer Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End-Use

10. South America Pediatric Cancer Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Type
    • 10.2.3. By End-Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pediatric Cancer Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End-Use
    • 10.3.2. Colombia Pediatric Cancer Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End-Use
    • 10.3.3. Argentina Pediatric Cancer Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pediatric Cancer Biomarkers Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Roche Diagnostics
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific
  • 15.3. Qiagen
  • 15.4. Abbott
  • 15.5. Illumina
  • 15.6. Bio-Rad
  • 15.7. Myriad Genetics
  • 15.8. Agilent
  • 15.9. Roche
  • 15.10. Takara Bio

16. Strategic Recommendations

17. About Us & Disclaimer